Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. The application has also been granted Priority Review. Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by Ast